晚期非小细胞肺癌基于PD-1/PD-L1抑制剂外周血生物标志物的研究进展
Research Progress on Peripheral Blood Biomarkers Based on PD-1/PD-L1 Inhibitors for Advanced Non-Small Cell Lung Cancer
DOI: 10.12677/acm.2024.14112855, PDF,   
作者: 苗雅楠：内蒙古医科大学第一临床医学院，内蒙古 呼和浩特；曹冉华*：内蒙古医科大学附属医院肿瘤内科，内蒙古 呼和浩特
关键词: 非小细胞肺癌；程序性死亡分子-1/程序性死亡分子配体-1；外周血生物标志物；Non-Small Cell Lung Cancer (NSCLC)； PD-1/PD-L1； Peripheral Blood Biomarkers
摘要: 近年来，晚期非小细胞肺癌(NSCLC)的治疗领域取得了显著进展，特别是以程序性死亡分子-1 (PD-1)及其配体(PD-L1)抑制剂为代表的免疫治疗，为这类患者提供了新的治疗选择。然而，如何精准预测PD-1/PD-L1抑制剂的治疗效果，筛选出优势人群，仍是当前研究的热点。本文综述了基于外周血生物标志物在预测晚期非小细胞肺癌患者PD-1/PD-L1抑制剂疗效中的研究进展。
Abstract: In recent years, significant progress has been made in the treatment of advanced non-small cell lung cancer (NSCLC), particularly with the advent of immunotherapy represented by programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors, which have provided new treatment options for these patients. However, precisely predicting the therapeutic effects of PD-1/PD-L1 inhibitors and identifying the advantageous patient population remain hot topics of current research. This article reviews the research progress on the use of peripheral blood biomarkers in predicting the efficacy of PD-1/PD-L1 inhibitors in patients with advanced NSCLC.
文章引用：苗雅楠, 曹冉华. 晚期非小细胞肺癌基于PD-1/PD-L1抑制剂外周血生物标志物的研究进展[J]. 临床医学进展, 2024, 14(11): 126-133. https://doi.org/10.12677/acm.2024.14112855

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] 郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220.
[3] 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2023版) [J]. 中国综合临床, 2023, 39(6): 401-423.
[4] Clark, G., Stockinger, H., Balderas, R., van Zelm, M.C., Zola, H., Hart, D., et al. (2016) Nomenclature of CD Molecules from the Tenth Human Leucocyte Differentiation Antigen Workshop. Clinical & Translational Immunology, 5, e57. [Google Scholar] [CrossRef] [PubMed]
[5] Olingy, C., Alimadadi, A., Araujo, D.J., Barry, D., Gutierrez, N.A., Werbin, M.H., et al. (2022) CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy against Non-Small Cell Lung Cancer. Frontiers in Immunology, 13, Article ID: 842653. [Google Scholar] [CrossRef] [PubMed]
[6] Fultang, L., Panetti, S., Ng, M., Collins, P., Graef, S., Rizkalla, N., et al. (2019) MDSC Targeting with Gemtuzumab Ozogamicin Restores T Cell Immunity and Immunotherapy against Cancers. EBioMedicine, 47, 235-246. [Google Scholar] [CrossRef] [PubMed]
[7] Bachanova, V. and Miller, J.S. (2014) NK Cells in Therapy of Cancer. Critical Reviews in Oncogenesis, 19, 133-141. [Google Scholar] [CrossRef] [PubMed]
[8] Hu, J., Zhang, L., Xia, H., Yan, Y., Zhu, X., Sun, F., et al. (2023) Tumor Microenvironment Remodeling after Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Revealed by Single-Cell RNA Sequencing. Genome Medicine, 15, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[9] Nikkhoi, S.K., Li, G., Eleya, S., Yang, G., Vandavasi, V.G. and Hatefi, A. (2023) Bispecific Killer Cell Engager with High Affinity and Specificity toward CD16a on NK Cells for Cancer Immunotherapy. Frontiers in Immunology, 13, Article ID: 1039969. [Google Scholar] [CrossRef] [PubMed]
[10] Kennedy, P.R., Vallera, D.A., Ettestad, B., Hallstrom, C., Kodal, B., Todhunter, D.A., et al. (2023) A Tri-Specific Killer Engager against Mesothelin Targets NK Cells towards Lung Cancer. Frontiers in Immunology, 14, Article ID: 1060905. [Google Scholar] [CrossRef] [PubMed]
[11] Picard, L.K., Claus, M., Fasbender, F. and Watzl, C. (2022) Human NK Cells Responses Are Enhanced by CD56 Engagement. European Journal of Immunology, 52, 1441-1451. [Google Scholar] [CrossRef] [PubMed]
[12] Sun, Y., Wan, J., Song, Q., Luo, C., Li, X., Luo, Y., et al. (2021) Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia. BioMed Research International, 2021, Article ID: 1929357. [Google Scholar] [CrossRef] [PubMed]
[13] Hui, G.K., Gao, X., Gor, J., Lu, J., Sun, P.D. and Perkins, S.J. (2023) The Solution Structure of the Unbound IGG Fc Receptor CD64 Resembles Its Crystal Structure: Implications for Function. PLOS ONE, 18, e0288351. [Google Scholar] [CrossRef] [PubMed]
[14] Elawady, S., Botros, S.K., Sorour, A.E., Ghany, E.A., Elbatran, G. and Ali, R. (2014) Neutrophil CD64 as a Diagnostic Marker of Sepsis in Neonates. Journal of Investigative Medicine, 62, 644-649. [Google Scholar] [CrossRef] [PubMed]
[15] Snyder, K.M., Dixon, K.J., Davis, Z., Hosking, M., Hart, G., Khaw, M., et al. (2023) iPSC-Derived Natural Killer Cells Expressing the FcγR Fusion CD64/16A Can Be Armed with Antibodies for Multitumor Antigen Targeting. Journal for ImmunoTherapy of Cancer, 11, e007280. [Google Scholar] [CrossRef] [PubMed]
[16] Liao, G., Zhao, Z., Qian, Y., Ling, X., Chen, S., Li, X., et al. (2021) Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 11, Article ID: 774131. [Google Scholar] [CrossRef] [PubMed]
[17] Yang, Q., Chen, M., Gu, J., Niu, K., Zhao, X., Zheng, L., et al. (2021) Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients. Frontiers in Immunology, 12, Article ID: 665133. [Google Scholar] [CrossRef] [PubMed]
[18] Tsai, J., Wei, S., Chen, C., Yang, S., Tseng, Y., Su, P., et al. (2022) Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio. Pharmaceuticals, 15, Article No. 1407. [Google Scholar] [CrossRef] [PubMed]
[19] Möller, M., Turzer, S., Ganchev, G., Wienke, A., Schütte, W., Seliger, B., et al. (2022) Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade. Cancers, 14, Article No. 3690. [Google Scholar] [CrossRef] [PubMed]
[20] Passiglia, F., Galvano, A., Castiglia, M., Incorvaia, L., Calò, V., Listì, A., et al. (2019) Monitoring Blood Biomarkers to Predict Nivolumab Effectiveness in NSCLC Patients. Therapeutic Advances in Medical Oncology, 11. [Google Scholar] [CrossRef] [PubMed]
[21] Rong, Y., Wu, W., Ni, X., Kuang, T., Jin, D., Wang, D., et al. (2013) Lactate Dehydrogenase a Is Overexpressed in Pancreatic Cancer and Promotes the Growth of Pancreatic Cancer Cells. Tumor Biology, 34, 1523-1530. [Google Scholar] [CrossRef] [PubMed]
[22] Le, A., Cooper, C.R., Gouw, A.M., Dinavahi, R., Maitra, A., Deck, L.M., et al. (2010) Inhibition of Lactate Dehydrogenase a Induces Oxidative Stress and Inhibits Tumor Progression. Proceedings of the National Academy of Sciences, 107, 2037-2042. [Google Scholar] [CrossRef] [PubMed]
[23] Xie, H., Valera, V.A., Merino, M.J., Amato, A.M., Signoretti, S., Linehan, W.M., et al. (2009) LDH-A Inhibition, a Therapeutic Strategy for Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer. Molecular Cancer Therapeutics, 8, 626-635. [Google Scholar] [CrossRef] [PubMed]
[24] Peng, L., Wang, Y., Liu, F., Qiu, X., Zhang, X., Fang, C., et al. (2020) Peripheral Blood Markers Predictive of Outcome and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors. Cancer Immunology, Immunotherapy, 69, 1813-1822. [Google Scholar] [CrossRef] [PubMed]
[25] Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., Yao, Y. and Zang, X. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway. Trends in Molecular Medicine, 21, 24-33. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, M., Yao, L., Cheng, M., Cai, D., Martinek, J., Pan, C., et al. (2018) Humanized Mice in Studying Efficacy and Mechanisms of PD‐1‐Targeted Cancer Immunotherapy. The FASEB Journal, 32, 1537-1549. [Google Scholar] [CrossRef] [PubMed]
[27] Alvarez, J.G.B., González-Cao, M., Karachaliou, N., et al. (2015) Advances in Immunotherapy for Treatment of Lung Cancer. Cancer Biology & Medicine, 12, 209-222.
[28] Wang, W., Zou, R., Qiu, Y., Liu, J., Xin, Y., He, T., et al. (2021) Interaction Networks Converging on Immunosuppressive Roles of Granzyme B: Special Niches within the Tumor Microenvironment. Frontiers in Immunology, 12, Article ID: 670324. [Google Scholar] [CrossRef] [PubMed]
[29] Qiao, D., Cheng, J., Yan, W. and Li, H. (2023) PD-L1/PD-1 Blockage Enhanced the Cytotoxicity of Natural Killer Cell on the Non-Small Cell Lung Cancer (NSCLC) by Granzyme B Secretion. Clinical and Translational Oncology, 25, 2373-2383. [Google Scholar] [CrossRef] [PubMed]
[30] Lam, M.S.Y., Reales-Calderon, J.A., Ow, J.R., Aw, J.J.Y., Tan, D., Vijayakumar, R., et al. (2023) G9a/GLP Inhibition during ex Vivo Lymphocyte Expansion Increases in Vivo Cytotoxicity of Engineered T Cells against Hepatocellular Carcinoma. Nature Communications, 14, Article No. 563. [Google Scholar] [CrossRef] [PubMed]
[31] Li, M., Chen, J., Yu, H., Zhang, B., Hou, X., Jiang, H., et al. (2023) Cerebrospinal Fluid Immunological Cytokines Predict Intracranial Tumor Response to Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases. OncoImmunology, 13, Article ID: 2290790. [Google Scholar] [CrossRef] [PubMed]
[32] Rosenberg, S.A. (2014) IL-2: The First Effective Immunotherapy for Human Cancer. The Journal of Immunology, 192, 5451-5458. [Google Scholar] [CrossRef] [PubMed]
[33] Lagunas-Cruz, M.d.C., Valle-Mendiola, A., Trejo-Huerta, J., Rocha-Zavaleta, L., Mora-García, M.d.L., Gutiérrez-Hoya, A., et al. (2019) IL-2 Induces Transient Arrest in the G1 Phase to Protect Cervical Cancer Cells from Entering Apoptosis. Journal of Oncology, 2019, Article ID: 7475295. [Google Scholar] [CrossRef] [PubMed]
[34] Sanmamed, M.F., Perez-Gracia, J.L., Schalper, K.A., Fusco, J.P., Gonzalez, A., Rodriguez-Ruiz, M.E., et al. (2017) Changes in Serum Interleukin-8 (IL-8) Levels Reflect and Predict Response to Anti-PD-1 Treatment in Melanoma and Non-Small-Cell Lung Cancer Patients. Annals of Oncology, 28, 1988-1995. [Google Scholar] [CrossRef] [PubMed]
[35] Kanoh, Y., Abe, T., Masuda, N. and Akahoshi, T. (2012) Progression of Non-Small Cell Lung Cancer: Diagnostic and Prognostic Utility of Matrix Metalloproteinase-2, C-Reactive Protein and Serum Amyloid A. Oncology Reports, 29, 469-473. [Google Scholar] [CrossRef] [PubMed]
[36] Moshkovskii, S.A. (2012) Why Do Cancer Cells Produce Serum Amyloid A Acute-Phase Protein? Biochemistry (Moscow), 77, 339-341. [Google Scholar] [CrossRef] [PubMed]
[37] Biaoxue, R., Hua, L., Wenlong, G. and Shuanying, Y. (2016) Increased Serum Amyloid a as Potential Diagnostic Marker for Lung Cancer: A Meta-Analysis Based on Nine Studies. BMC Cancer, 16, Article No. 836. [Google Scholar] [CrossRef] [PubMed]

为你推荐